SG11201900651PA - Combination of fxr agonists - Google Patents
Combination of fxr agonistsInfo
- Publication number
- SG11201900651PA SG11201900651PA SG11201900651PA SG11201900651PA SG11201900651PA SG 11201900651P A SG11201900651P A SG 11201900651PA SG 11201900651P A SG11201900651P A SG 11201900651PA SG 11201900651P A SG11201900651P A SG 11201900651PA SG 11201900651P A SG11201900651P A SG 11201900651PA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- novartis
- basel
- pct
- applicant
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Emergency Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662394446P | 2016-09-14 | 2016-09-14 | |
| PCT/IB2017/055503 WO2018051230A1 (en) | 2016-09-14 | 2017-09-12 | Combination of fxr agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201900651PA true SG11201900651PA (en) | 2019-04-29 |
Family
ID=60043251
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201900651PA SG11201900651PA (en) | 2016-09-14 | 2017-09-12 | Combination of fxr agonists |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US20210290610A1 (de) |
| EP (1) | EP3512558A1 (de) |
| JP (1) | JP6878596B2 (de) |
| KR (1) | KR102218498B1 (de) |
| CN (1) | CN109689105A (de) |
| AR (1) | AR109652A1 (de) |
| AU (2) | AU2017328999B2 (de) |
| BR (1) | BR112019004684A2 (de) |
| CA (1) | CA3036760A1 (de) |
| CL (1) | CL2019000625A1 (de) |
| CO (1) | CO2019002245A2 (de) |
| CR (1) | CR20190125A (de) |
| EC (1) | ECSP19016844A (de) |
| IL (1) | IL264628A (de) |
| JO (1) | JOP20190040A1 (de) |
| MX (1) | MX2019003021A (de) |
| PE (1) | PE20190972A1 (de) |
| PH (1) | PH12019500326A1 (de) |
| RU (1) | RU2019110780A (de) |
| SG (1) | SG11201900651PA (de) |
| TW (1) | TW201811372A (de) |
| WO (1) | WO2018051230A1 (de) |
| ZA (1) | ZA201900528B (de) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN110418641A (zh) * | 2017-02-24 | 2019-11-05 | 基恩菲特公司 | 用于组合疗法的药物组合物 |
| AU2019276955A1 (en) | 2018-05-31 | 2020-12-03 | Novartis Ag | Combinations comprising tropifexor and cenicriviroc |
| EP3999100A1 (de) * | 2019-07-18 | 2022-05-25 | ENYO Pharma | Verbesserte behandlung mit eyp001 |
| AU2020405182B2 (en) * | 2019-12-20 | 2024-03-14 | Novartis Ag | Combination treatment of liver diseases using integrin inhibitors |
| CN112402430A (zh) * | 2020-12-11 | 2021-02-26 | 大连医科大学 | 泽泻醇b-23-醋酸酯在预防和治疗急性肾损伤中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6987121B2 (en) * | 2002-04-25 | 2006-01-17 | Smithkline Beecham Corporation | Compositions and methods for hepatoprotection and treatment of cholestasis |
| SI2370442T1 (sl) * | 2008-11-26 | 2013-06-28 | Pfizer Inc. | 3-aminociklopentankarboksiamidi kot modulatorji kemokinskega receptorja |
| US8383812B2 (en) | 2009-10-13 | 2013-02-26 | Bristol-Myers Squibb Company | N-((1R,2S,5R)-5-(tert-butylamino)-2-((S)-3-(7-tert-butylpyrazolo[1,5-A][1,3,5]triazin-4-ylamino)-2-oxopyrrolidin-1-yl)cyclohexyl)acetamide, a dual modulator of chemokine receptor activity, crystalline forms and processes |
| CU24152B1 (es) * | 2010-12-20 | 2016-02-29 | Irm Llc | 1,2 oxazol-8-azabiciclo[3,2,1]octano 8 il como moduladores de fxr |
| CN105682656B (zh) * | 2013-11-05 | 2019-11-05 | 诺华股份有限公司 | 调节法尼醇x受体的组合物和方法 |
| KR20160132111A (ko) * | 2014-03-13 | 2016-11-16 | 더 솔크 인스티튜트 포 바이올로지칼 스터디즈 | Fxr 작용제와 제조방법 및 용도 |
| EP3191100A4 (de) * | 2014-09-12 | 2018-05-30 | Tobira Therapeutics, Inc. | Cenicriviroc-kombinationstherapie zur behandlung von fibrose |
| CN107106555A (zh) * | 2014-12-18 | 2017-08-29 | 诺华股份有限公司 | 氮杂双环辛烷衍生物作为fxr激动剂在治疗肝脏和胃肠疾病中的应用 |
| JP6941109B2 (ja) * | 2016-02-22 | 2021-09-29 | ノバルティス アーゲー | Ｆｘｒアゴニストを使用するための方法 |
-
2017
- 2017-06-16 JO JOP/2019/0040A patent/JOP20190040A1/ar unknown
- 2017-09-12 RU RU2019110780A patent/RU2019110780A/ru not_active Application Discontinuation
- 2017-09-12 CN CN201780056097.XA patent/CN109689105A/zh active Pending
- 2017-09-12 CA CA3036760A patent/CA3036760A1/en not_active Abandoned
- 2017-09-12 SG SG11201900651PA patent/SG11201900651PA/en unknown
- 2017-09-12 KR KR1020197009426A patent/KR102218498B1/ko active IP Right Grant
- 2017-09-12 AU AU2017328999A patent/AU2017328999B2/en not_active Ceased
- 2017-09-12 MX MX2019003021A patent/MX2019003021A/es unknown
- 2017-09-12 WO PCT/IB2017/055503 patent/WO2018051230A1/en active Application Filing
- 2017-09-12 JP JP2019535998A patent/JP6878596B2/ja active Active
- 2017-09-12 CR CR20190125A patent/CR20190125A/es unknown
- 2017-09-12 EP EP17781186.6A patent/EP3512558A1/de not_active Withdrawn
- 2017-09-12 US US16/332,446 patent/US20210290610A1/en not_active Abandoned
- 2017-09-12 PE PE2019000497A patent/PE20190972A1/es unknown
- 2017-09-12 BR BR112019004684A patent/BR112019004684A2/pt not_active IP Right Cessation
- 2017-09-14 AR ARP170102541A patent/AR109652A1/es unknown
- 2017-09-14 TW TW106131530A patent/TW201811372A/zh unknown
-
2019
- 2019-01-25 ZA ZA2019/00528A patent/ZA201900528B/en unknown
- 2019-02-03 IL IL264628A patent/IL264628A/en unknown
- 2019-02-15 PH PH12019500326A patent/PH12019500326A1/en unknown
- 2019-03-11 EC ECSENADI201916844A patent/ECSP19016844A/es unknown
- 2019-03-12 CL CL2019000625A patent/CL2019000625A1/es unknown
- 2019-04-15 CO CONC2019/0002245A patent/CO2019002245A2/es unknown
-
2020
- 2020-03-19 AU AU2020201980A patent/AU2020201980A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| IL264628A (en) | 2019-02-28 |
| WO2018051230A1 (en) | 2018-03-22 |
| BR112019004684A2 (pt) | 2019-05-28 |
| JOP20190040A1 (ar) | 2019-03-10 |
| CN109689105A (zh) | 2019-04-26 |
| AU2020201980A1 (en) | 2020-04-09 |
| JP6878596B2 (ja) | 2021-05-26 |
| CA3036760A1 (en) | 2018-03-22 |
| EP3512558A1 (de) | 2019-07-24 |
| CO2019002245A2 (es) | 2019-05-31 |
| KR20190044666A (ko) | 2019-04-30 |
| AU2017328999A1 (en) | 2019-02-21 |
| CL2019000625A1 (es) | 2019-05-17 |
| AR109652A1 (es) | 2019-01-09 |
| TW201811372A (zh) | 2018-04-01 |
| ECSP19016844A (es) | 2019-03-29 |
| MX2019003021A (es) | 2019-09-26 |
| PH12019500326A1 (en) | 2019-11-11 |
| JP2019526644A (ja) | 2019-09-19 |
| AU2017328999B2 (en) | 2019-12-19 |
| KR102218498B1 (ko) | 2021-02-22 |
| RU2019110780A (ru) | 2020-10-15 |
| CR20190125A (es) | 2019-06-04 |
| ZA201900528B (en) | 2021-06-30 |
| US20210290610A1 (en) | 2021-09-23 |
| PE20190972A1 (es) | 2019-07-09 |
| RU2019110780A3 (de) | 2020-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201908330PA (en) | Farnesoid x receptor agonists and uses thereof | |
| SG11201900651PA (en) | Combination of fxr agonists | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201902938TA (en) | Compounds, devices, and uses thereof | |
| SG11201811564QA (en) | Methods of treating ovarian cancer | |
| SG11201808990QA (en) | Compositions for topical application of compounds | |
| SG11201908420WA (en) | Compositions of plinabulin and use thereof | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201907604UA (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan | |
| SG11201908512YA (en) | Somatostatin modulators and uses thereof | |
| SG11201811230RA (en) | Compositions and methods for reducing ocular neovascularization | |
| SG11201807597UA (en) | Methods of treating depression using orexin-2 receptor antagonists | |
| SG11201900349VA (en) | Somatostatin modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201908517XA (en) | Pyrimidinyl-pyridyloxy-naphthyl compounds and methods of treating ire1-related diseases and disorders | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201804673WA (en) | Novel anti-claudin antibodies and methods of use | |
| SG11201811559WA (en) | Cancer treatment combinations | |
| SG11201809751XA (en) | Egfr inhibitor compounds | |
| SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
| SG11201806133UA (en) | Intermediates in the synthesis of eribulin and related methods of synthesis | |
| SG11201901063SA (en) | Therapeutic agents for neurodegenerative diseases | |
| SG11201906164RA (en) | Bicyclic inhibitors of histone deacetylase | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer |